Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 524308, 15 pages
http://dx.doi.org/10.1155/2012/524308
Review Article

The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias

1Department of Biochemistry and Molecular Biology, University of Athens, Panepistimiopolis, 15701 Athens, Greece
2“Aghia Sophia” Children's Hospital, Thibon & Papadiamantopoulou, 11527 Athens, Greece
3Second Department of Internal Medicine—Propaedeutic, Hematology Unit, University of Athens, Medical School, University General Hospital “Attikon”, 1 Rimini Street, 12462 Haidari, Greece
4Research Laboratories, 2nd Department of Pediatrics, Medical School, University of Athens, P & A Kyriakou Children's Hospital Thivon & Levadeias, 11527 Athens, Greece
5First Department of Oncology, St. Savvas Anticancer Hospital, 171, Alexandras Avenue, 11522 Athens, Greece

Received 6 March 2011; Revised 22 May 2011; Accepted 27 June 2011

Academic Editor: Michael H. Tomasson

Copyright © 2012 Flora Tzifi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Yuan, M. Lipinski, and A. Degterev, “Diversity in the mechanisms of neuronal cell death,” Neuron, vol. 40, no. 2, pp. 401–413, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. K. C. Zimmermann and D. R. Green, “How cells die: apoptosis pathways,” Journal of Allergy and Clinical Immunology, vol. 108, supplement 4, pp. S99–S103, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. S. W. G. Tait and D. R. Green, “Mitochondria and cell death: outer membrane permeabilization and beyond,” Nature Reviews Molecular Cell Biology, vol. 11, no. 9, pp. 621–632, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998. View at Google Scholar · View at Scopus
  5. Y. Tsujimoto, J. Gorham, and J. Cossman, “The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining,” Science, vol. 229, no. 4720, pp. 1390–1393, 1985. View at Google Scholar · View at Scopus
  6. S. Cory and J. M. Adams, “The BCL2 family: regulators of the cellular life-or-death switch,” Nature Reviews Cancer, vol. 2, no. 9, pp. 647–656, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. B. M. Pickering, S. De Mel, M. Lee et al., “Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells,” Oncogene, vol. 26, no. 8, pp. 1166–1177, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. H. Walczak and P. H. Krammer, “The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems,” Experimental Cell Research, vol. 256, no. 1, pp. 58–66, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. H. Thomadaki and A. Scorilas, “BCL2 family of apoptosis-related genes: functions and clinical implications in cancer,” Critical Reviews in Clinical Laboratory Sciences, vol. 43, no. 1, pp. 1–67, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. A. Scorilas, L. Kyriakopoulou, G. M. Yousef, L. K. Ashworth, A. Kwamie, and E. P. Diamandis, “Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family,” Genomics, vol. 72, no. 2, pp. 217–221, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. M. Talieri, E. P. Diamandis, N. Katsaros, D. Gourgiotis, and A. Scorilas, “Expression of BCL2L12, a new member of apoptosis-related genes, in breast tumors,” Thrombosis and Haemostasis, vol. 89, no. 6, pp. 1081–1088, 2003. View at Google Scholar · View at Scopus
  12. K. Mathioudaki, A. Scorilas, A. Papadokostopoulou et al., “Expression analysis of BCL2L12, a new member of apoptosis-related genes, in colon cancer,” Biological Chemistry, vol. 385, no. 9, pp. 779–783, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. H. Thomadaki, M. Talieri, and A. Scorilas, “Prognostic value of the apoptosis related genes BCL2 and BCL2L12 in breast cancer,” Cancer Letters, vol. 247, no. 1-2, pp. 48–55, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. H. Thomadaki, M. Talieri, and A. Scorilas, “Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS,” Biological Chemistry, vol. 387, no. 8, pp. 1081–1086, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. A. Sklavounou, E. Chrysomali, A. Scorilas, and A. Karameris, “TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation,” Journal of Oral Pathology and Medicine, vol. 29, no. 8, pp. 370–375, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Kalomenidis, D. Orphanidou, G. Papamichalis et al., “Combined expression of p53, Bcl-2, and p21WAF-1 proteins in lung cancer and premalignant lesions: association with clinical characteristics,” Lung, vol. 179, no. 5, pp. 265–278, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. C. Reed, “Proapoptotic multidomain Bcl-2/Bax-family proteins: mechanisms, physiological roles, and therapeutic opportunities,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1378–1386, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. M. Adams and S. Cory, “The Bcl-2 protein family: arbiters of cell survival,” Science, vol. 281, no. 5381, pp. 1322–1326, 1998. View at Google Scholar · View at Scopus
  19. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. J. C. Reed, “Apoptosis mechanisms: implications for cancer drug discovery,” Oncology, vol. 18, supplement 10, no. 13, pp. 11–20, 2004. View at Google Scholar · View at Scopus
  21. S. J. Korsmeyer, “Bcl-2: an antidote to programmed cell death,” Cancer Surveys, vol. 15, pp. 105–118, 1992. View at Google Scholar · View at Scopus
  22. L. Khemtemourian, M. A. Sani, K. Bathany, G. Grobner, and E. J. Dufourc, “Synthesis and secondary structure in membranes of the Bcl-2 anti-apoptotic domain BH4,” Journal of Peptide Science, vol. 12, no. 1, pp. 58–64, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. Simonen, H. Keller, and J. Heim, “The BH3 domain of Bax is sufficient for interaction of Bax with itself and with other family members and it is required for induction of apoptosis,” European Journal of Biochemistry, vol. 249, no. 1, pp. 85–91, 1997. View at Google Scholar · View at Scopus
  24. D. S. Bellows, B. N. Chau, L. Percy, Y. Lazebnik, W. H. Burns, and J. M. Hardwick, “Antiapoptotic herpesvirus Bcl-2 homologs escape caspase-mediated conversion to proapoptotic proteins,” Journal of Virology, vol. 74, no. 11, pp. 5024–5031, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. H. F. Yang-Yen, “Mcl-1: a highly regulated cell death and survival controller,” Journal of Biomedical Science, vol. 13, no. 2, pp. 201–204, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. D. P. Stewart, B. Koss, M. Bathina, R. M. Perciavalle, K. Bisanz, and J. T. Opferman, “Ubiquitin-independent degradation of antiapoptotic MCL-1,” Molecular and Cellular Biology, vol. 30, no. 12, pp. 3099–3110, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. Akgul, “Mcl-1 is a potential therapeutic target in multiple types of cancer,” Cellular and Molecular Life Sciences, vol. 66, no. 8, pp. 1326–1336, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. B. Leibowitz and J. Yu, “Mitochondrial signaling in cell death via the Bcl-2 family,” Cancer Biology and Therapy, vol. 9, no. 6, pp. 417–422, 2010. View at Google Scholar · View at Scopus
  29. A. M. Petros, E. T. Olejniczak, and S. W. Fesik, “Structural biology of the Bcl-2 family of proteins,” Biochimica et Biophysica Acta, vol. 1644, no. 2-3, pp. 83–94, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. L. D. Walensky, “BCL-2 in the crosshairs: tipping the balance of life and death,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1339–1350, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Klee and F. X. Pimentel-Muinos, “Bcl-X(L) specifically activates Bak to induce swelling and restructuring of the endoplasmic reticulum,” Journal of Cell Biology, vol. 168, no. 5, pp. 723–734, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. J. E. Chipuk, T. Kuwana, L. Bouchier-Hayes et al., “Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis,” Science, vol. 303, no. 5660, pp. 1010–1014, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. D. E. Wood, A. Thomas, L. A. Devi et al., “Bax cleavage is mediated by calpain during drug-induced apoptosis,” Oncogene, vol. 17, no. 9, pp. 1069–1078, 1998. View at Google Scholar · View at Scopus
  34. J. Zha, H. Harada, E. Yang, J. Jockel, and S. J. Korsmeyer, “Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L),” Cell, vol. 87, no. 4, pp. 619–628, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Zhu, G. Y. Yang, B. Ahlemeyer et al., “Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage,” Journal of Neuroscience, vol. 22, no. 10, pp. 3898–3909, 2002. View at Google Scholar · View at Scopus
  36. S. Zinkel, A. Gross, and E. Yang, “BCL2 family in DNA damage and cell cycle control,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1351–1359, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. S. S. Zinkel, C. C. Ong, D. O. Ferguson et al., “Proapoptotic BID is required for myeloid homeostasis and tumor suppression,” Genes and Development, vol. 17, no. 2, pp. 229–239, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. K. Wang, X. M. Yin, D. T. Chao, C. L. Milliman, and S. J. Korsmeyer, “BID: a novel BH3 domain-only death agonist,” Genes and Development, vol. 10, no. 22, pp. 2859–2869, 1996. View at Google Scholar · View at Scopus
  39. X. Luo, I. Budihardjo, H. Zou, C. Slaughter, and X. Wang, “Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors,” Cell, vol. 94, no. 4, pp. 481–490, 1998. View at Google Scholar · View at Scopus
  40. A. B. Werner, S. W. G. Tait, E. De Vries, E. Eldering, and J. Borst, “Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens,” Journal of Biological Chemistry, vol. 279, no. 27, pp. 28771–28780, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. T. Kuwana, L. Bouchier-Hayes, J. E. Chipuk et al., “BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly,” Molecular Cell, vol. 17, no. 4, pp. 525–535, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. I. Wojcik, M. Szybka, E. Golanska et al., “Abnormalities of the P53, MDM2, BCL2 and BAX genes in acute leukemias,” Neoplasma, vol. 52, no. 4, pp. 318–324, 2005. View at Google Scholar · View at Scopus
  43. P. Menendez, A. Vargas, C. Bueno et al., “Quantitative analysis of bcl-2 expression in normal and leukemic human B-cell differentiation,” Leukemia, vol. 18, no. 3, pp. 491–498, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. D. Campana, E. Coustan-Smith, A. Manabe et al., “Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein,” Blood, vol. 81, no. 4, pp. 1025–1031, 1993. View at Google Scholar · View at Scopus
  45. S. Aref, O. Salama, Y. Al-Tonbary, and A. Mansour, “Assessment of bcl-2 expression ass modulator of Fas mediated apoptosis in acute leukemia,” Hematology, vol. 9, no. 2, pp. 113–121, 2004. View at Google Scholar · View at Scopus
  46. G. R. Sahu and B. R. Das, “Prognostic significance of p53 and Bcl-2 in acute lymphoblastic leukemia,” Oncology Reports, vol. 9, no. 6, pp. 1391–1398, 2002. View at Google Scholar · View at Scopus
  47. L. Campos, O. Sabido, C. Sebban et al., “Expression of BCL-2 proto-oncogene in adult acute lymphoblastic leukemia,” Leukemia, vol. 10, no. 3, pp. 434–438, 1996. View at Google Scholar · View at Scopus
  48. L. A. Hogarth and A. G. Hall, “Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia,” Blood, vol. 93, no. 8, pp. 2671–2678, 1999. View at Google Scholar · View at Scopus
  49. E. Coustan-Smith, A. Kitanaka, C. H. Pui et al., “Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia,” Blood, vol. 87, no. 3, pp. 1140–1146, 1996. View at Google Scholar · View at Scopus
  50. M. I. Del Principe, G. Del Poeta, L. Maurillo et al., “P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia,” British Journal of Haematology, vol. 121, no. 5, pp. 730–738, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Feng, D. L. Stachura, R. M. White et al., “T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation,” Cancer Cell, vol. 18, no. 4, pp. 353–366, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. A. Prokop, T. Wieder, I. Sturm et al., “Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo,” Leukemia, vol. 14, no. 9, pp. 1606–1613, 2000. View at Google Scholar · View at Scopus
  53. P. J. Swanson, S. L. Kuslak, W. Fang et al., “Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc,” Journal of Immunology, vol. 172, no. 11, pp. 6684–6691, 2004. View at Google Scholar · View at Scopus
  54. R. Addeo, M. Caraglia, A. Baldi et al., “Prognostic role of bcl-xL and p53 in childhood acute lymphoblastic leukemia (ALL),” Cancer Biology and Therapy, vol. 4, no. 1, pp. 32–38, 2005. View at Google Scholar · View at Scopus
  55. J. F. Mata, V. S. Silveira, E. C. Mateo et al., “Low mRNA expression of the apoptosis-related genes CASP3, CASP8, and FAS is associated with low induction treatment response in childhood acute lymphoblastic leukemia (ALL),” Pediatric Blood and Cancer, vol. 55, no. 1, pp. 100–107, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. E. Laane, E. Tani, E. Bjorklund et al., “Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma,” Cytometry Part B, vol. 64, no. 1, pp. 34–42, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. C. Ploner, J. Rainer, S. Lobenwein, S. Geley, and R. Kofler, “Repression of the BH3-only molecule PMAIP1/Noxa impairs glucocorticoid sensitivity of acute lymphoblastic leukemia cells,” Apoptosis, vol. 14, no. 6, pp. 821–828, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. Holleman, M. L. Den Boer, R. X. De Menezes et al., “The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia,” Blood, vol. 107, no. 2, pp. 769–776, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. M. Andreeff, S. Jiang, X. Zhang et al., “Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid,” Leukemia, vol. 13, no. 11, pp. 1881–1892, 1999. View at Google Scholar · View at Scopus
  60. D. Milojkovic, S. Devereux, N. B. Westwood, G. J. Mufti, N. S. B. Thomas, and A. G. S. Buggins, “Antiapoptotic microenvironment of acute myeloid leukemia,” Journal of Immunology, vol. 173, no. 11, pp. 6745–6752, 2004. View at Google Scholar · View at Scopus
  61. A. G. S. Buggins, D. Milojkovic, M. J. Arno et al., “Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways,” Journal of Immunology, vol. 167, no. 10, pp. 6021–6030, 2001. View at Google Scholar · View at Scopus
  62. A. Venditti, G. Del Poeta, L. Maurillo et al., “Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia,” Haematologica, vol. 89, no. 8, pp. 934–939, 2004. View at Google Scholar · View at Scopus
  63. C. Wuchter, L. Karawajew, V. Ruppert et al., “Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics,” Leukemia, vol. 13, no. 12, pp. 1943–1953, 1999. View at Google Scholar · View at Scopus
  64. S. M. Kornblau, P. F. Thall, Z. Estrov et al., “The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics,” Clinical Cancer Research, vol. 5, no. 7, pp. 1758–1766, 1999. View at Google Scholar · View at Scopus
  65. L. Klampfer, J. Zhang, A. O. Zelenetz, H. Uchida, and S. D. Nimer, “The AML1/ETO fusion protein activates transcription of BCL-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 24, pp. 14059–14064, 1996. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Shikami, H. Miwa, K. Nishii et al., “Low BCL-2 expression in acute leukemia with t(8;21) chromosomal abnormality,” Leukemia, vol. 13, no. 3, pp. 358–368, 1999. View at Google Scholar · View at Scopus
  67. T. Karakas, U. Maurer, E. Weidmann, C. C. Miething, D. Hoelzer, and L. Bergmann, “High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia,” Annals of Oncology, vol. 9, no. 2, pp. 159–165, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. T. Kohler, C. Schill, M. W. Deininger et al., “High bad and bax mRNA expression correlate with negative outcome in acute myeloid leukemia (AML),” Leukemia, vol. 16, no. 1, pp. 22–29, 2002. View at Publisher · View at Google Scholar · View at Scopus
  69. Y. L. Ong, M. F. McMullin, K. E. M. Bailie, T. R. J. Lappin, F. G. C. Jones, and A. E. Irvine, “High bax expression is a good prognostic indicator in acute myeloid leukaemia,” British Journal of Haematology, vol. 111, no. 1, pp. 182–189, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Yamaguchi, K. Inokuchi, and K. Dan, “The study for loss of bcl-xs expression as a prognostic factor in acute myeloid leukemia,” Leukemia Research, vol. 26, no. 12, pp. 1119–1123, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. S. M. Kornblau, H. T. Vu, P. Ruvolo et al., “BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia,” Clinical Cancer Research, vol. 6, no. 4, pp. 1401–1409, 2000. View at Google Scholar · View at Scopus
  72. C. Rochlitz, A. Lohri, M. Bacchi et al., “Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK),” Leukemia, vol. 13, no. 9, pp. 1352–1358, 1999. View at Google Scholar · View at Scopus
  73. D. Bradbury, S. Rogers, R. Kozlowski, G. Bowen, I. A. G. Reilly, and N. H. Russell, “Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia,” British Journal of Haematology, vol. 76, no. 4, pp. 488–493, 1990. View at Google Scholar · View at Scopus
  74. S. Spiegel and S. Milstien, “Sphingosine-1-phosphate: an enigmatic signalling lipid,” Nature Reviews Molecular Cell Biology, vol. 4, no. 5, pp. 397–407, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. J. Turzanski, M. Grundy, N. H. Russell, and M. Pallis, “Interleukin-1beta maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways,” Leukemia, vol. 18, no. 10, pp. 1662–1670, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. H. Asao and X. Y. Fu, “Interferon-gamma has dual potentials in inhibiting or promoting cell proliferation,” Journal of Biological Chemistry, vol. 275, no. 2, pp. 867–874, 2000. View at Publisher · View at Google Scholar · View at Scopus
  77. S. Faderl, D. Harris, Q. Van, H. M. Kantarjian, M. Talpaz, and Z. Estrov, “Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia,” Blood, vol. 102, no. 2, pp. 630–637, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. M. Milella, Z. Estrov, S. M. Kornblau et al., “Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia,” Blood, vol. 99, no. 9, pp. 3461–3464, 2002. View at Publisher · View at Google Scholar · View at Scopus
  79. I. N. Karnolsky, “Cytogenetic abnormalities in chronic lymphocytic leukemia,” Folia Medica, vol. 42, no. 3, pp. 5–10, 2000. View at Google Scholar · View at Scopus
  80. A. Cimmino, G. A. Calin, M. Fabbri et al., “miR-15 and miR-16 induce apoptosis by targeting BCL2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 39, pp. 13944–13949, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. G. A. Calin, A. Cimmino, M. Fabbri et al., “MiR-15a and miR-16-1 cluster functions in human leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 13, pp. 5166–5171, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. H. Nuckel, U. H. Frey, M. Bau et al., “Association of a novel regulatory polymorphism (938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia,” Blood, vol. 109, no. 1, pp. 290–297, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. A. Majid, O. Tsoulakis, R. Walewska et al., “BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938C>A promoter single nucleotide polymorphism,” Blood, vol. 111, no. 2, pp. 874–877, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. C. Pepper, T. Hoy, and P. Bentley, “Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance,” Leukemia and Lymphoma, vol. 28, no. 3-4, pp. 355–361, 1998. View at Google Scholar · View at Scopus
  85. S. Skogsberg, G. Tobin, A. Krober et al., “The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia,” Leukemia, vol. 20, no. 1, pp. 77–81, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. O. Moshynska, K. Sankaran, P. Pahwa, and A. Saxena, “Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia,” Journal of the National Cancer Institute, vol. 96, no. 9, pp. 673–682, 2004. View at Google Scholar · View at Scopus
  87. G. Packham and F. K. Stevenson, “Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia,” Immunology, vol. 114, no. 4, pp. 441–449, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. S. Kitada, J. Andersen, S. Akar et al., “Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses,” Blood, vol. 91, no. 9, pp. 3379–3389, 1998. View at Google Scholar · View at Scopus
  89. L. E. Robertson, W. Plunkett, K. McConnell, M. J. Keating, and T. J. McDonnell, “Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome,” Leukemia, vol. 10, no. 3, pp. 456–459, 1996. View at Google Scholar · View at Scopus
  90. S. Molica, A. Dattilo, C. Giulino, D. Levato, and L. Levato, “Increased bcl-2/bax ratio in B-cell chronic lymphocytic leukemia is associated with a progressive pattern of disease,” Haematologica, vol. 83, no. 12, pp. 1122–1124, 1998. View at Google Scholar · View at Scopus
  91. M. Aguilar-Santelises, M. E. Rottenberg, N. Lewin, H. Mellstedt, and M. Jondal, “bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression,” International Journal of Cancer, vol. 69, no. 2, pp. 114–119, 1996. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Molica, A. Mannella, G. Crispino, A. Dattilo, and D. Levato, “Comparative flow cytometric evaluation of bcl-2 oncoprotein in CD5+ and CD5- B-cell lymphoid chronic leukemias,” Haematologica, vol. 82, no. 5, pp. 555–559, 1997. View at Google Scholar · View at Scopus
  93. S. Faderl, M. J. Keating, K. A. Do et al., “Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL),” Leukemia, vol. 16, no. 6, pp. 1045–1052, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. J. R. Faria, M. Yamamoto, R. M. D. Faria, J. Kerbauy, and J. S. R. Oliveira, “Fludarabine induces apoptosis in chronic lymphocytic leukemia—the role of P53, Bcl-2, Bax, Mcl-1 and Bag-1 proteins,” Brazilian Journal of Medical and Biological Research, vol. 39, no. 3, pp. 327–333, 2006. View at Publisher · View at Google Scholar · View at Scopus
  95. A. A. Morales, A. Olsson, F. Celsing, A. Osterborg, M. Jondal, and L. M. Osorio, “High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia,” International Journal of Cancer, vol. 113, no. 5, pp. 730–737, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. Olsson, M. Norberg, A. Okvist et al., “Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia,” British Journal of Cancer, vol. 97, no. 6, pp. 769–777, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. A. Saxena, S. Viswanathan, O. Moshynska, P. Tandon, K. Sankaran, and D. P. Sheridan, “Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia,” American Journal of Hematology, vol. 75, no. 1, pp. 22–33, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. M. Klobusicka, J. Kusenda, and O. Babusikova, “Immunocytochemical detection of bcl-2 and p53 proteins in B-chronic lymphocytic leukemia patients,” Neoplasma, vol. 49, no. 6, pp. 387–393, 2002. View at Google Scholar · View at Scopus
  99. A. Lazaridou, C. Miraxtsi, J. Korantzis, N. Eleftheriadis, and J. I. Christakis, “Simultaneous detection of BCL-2 protein, trisomy 12, retinoblastoma and p53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): relation to disease status,” Leukemia and Lymphoma, vol. 36, no. 5-6, pp. 503–512, 2000. View at Google Scholar · View at Scopus
  100. S. Duensing, A. Nasarek, J. Grosse, A. Ganser, and J. Atzpodien, “Elevated plasma levels of interleukin-1 receptor antagonist are associated with decreased cellular BCL-2 oncoprotein expression in B-chronic lymphocytic leukemia,” Cancer Biotherapy and Radiopharmaceuticals, vol. 13, no. 5, pp. 383–385, 1998. View at Google Scholar
  101. R. R. Furman, Z. Asgary, J. O. Mascarenhas, H. C. Liou, and E. J. Schattner, “Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells,” Journal of Immunology, vol. 164, no. 4, pp. 2200–2206, 2000. View at Google Scholar · View at Scopus
  102. S. Cuni, P. Perez-Aciego, G. Perez-Chacon et al., “A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells,” Leukemia, vol. 18, no. 8, pp. 1391–1400, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. J. Zhuang, S. F. Hawkins, M. A. Glenn et al., “Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition,” Haematologica, vol. 95, no. 1, pp. 110–118, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. S. Jaiswal, D. Traver, T. Miyamoto, K. Akashi, E. Lagasse, and I. L. Weissman, “Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 17, pp. 10002–10007, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. H. Handa, U. P. Hegde, V. M. Kotelnikov et al., “Bcl-2 and c-myc expression, cell cycle kinetics and apoptosis during the progression of chronic myelogenous leukemia from diagnosis to blastic phase,” Leukemia Research, vol. 21, no. 6, pp. 479–489, 1997. View at Publisher · View at Google Scholar · View at Scopus
  106. S. O. Freytag, “Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1,” Molecular and Cellular Biology, vol. 8, no. 4, pp. 1614–1624, 1988. View at Google Scholar · View at Scopus
  107. K. Shuai, J. Halpern, J. T. Hoeve, X. Rao, and C. L. Sawyers, “Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia,” Oncogene, vol. 13, no. 2, pp. 247–254, 1996. View at Google Scholar · View at Scopus
  108. J. E. Darnell Jr., “STATs and gene regulation,” Science, vol. 277, no. 5332, pp. 1630–1635, 1997. View at Publisher · View at Google Scholar · View at Scopus
  109. M. S. Neshat, A. B. Raitano, H. G. Wang, J. C. Reed, and C. L. Sawyers, “The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf,” Molecular and Cellular Biology, vol. 20, no. 4, pp. 1179–1186, 2000. View at Publisher · View at Google Scholar · View at Scopus
  110. K. Keeshan, T. G. Cotter, and S. L. McKenna, “High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion,” Leukemia, vol. 16, no. 9, pp. 1725–1734, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. T. Shinjyo, R. Kuribara, T. Inukai et al., “Downregulation of Bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors,” Molecular and Cellular Biology, vol. 21, no. 3, pp. 854–864, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. R. Kuribara, H. Honda, H. Matsui et al., “Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors,” Molecular and Cellular Biology, vol. 24, no. 14, pp. 6172–6183, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  113. K. J. Aichberger, M. Mayerhofer, M. T. Krauth et al., “Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides,” Blood, vol. 105, no. 8, pp. 3303–3311, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. S. M. O'Brien, C. C. Cunningham, A. K. Golenkov, A. G. Turkina, S. C. Novick, and K. R. Rai, “Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7697–7702, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  115. N. W. C. van de Donk, M. M. J. Kamphuis, M. van Dijk, H. P. E. Borst, A. C. Bloem, and H. M. Lokhorst, “Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein,” Leukemia, vol. 17, no. 1, pp. 211–219, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. M. R. Smith, Y. Abubakr, R. Mohammad, T. Xie, M. Hamdan, and A. al-Katib, “Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL,” Cancer Gene Therapy, vol. 2, no. 3, pp. 207–212, 1995. View at Google Scholar · View at Scopus
  117. M. J. Keating, S. O'Brien, M. Albitar et al., “Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 23, no. 18, pp. 4079–4088, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. A. Chanan-Khan, “Bcl-2 antisense therapy in B-cell malignancies,” Blood Reviews, vol. 19, no. 4, pp. 213–221, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  119. G. Marcucci, W. Stock, G. Dai et al., “Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity,” Journal of Clinical Oncology, vol. 23, no. 15, pp. 3404–3411, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  120. G. Marcucci, J. C. Byrd, G. Dai et al., “Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia,” Blood, vol. 101, no. 2, pp. 425–432, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  121. F. J. Giles, “New drugs in acute myeloid leukemia,” Current Oncology Reports, vol. 4, no. 5, pp. 369–374, 2002. View at Google Scholar · View at Scopus
  122. K. V. Floros, M. Talieri, and A. Scorilas, “Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells,” Biological Chemistry, vol. 387, no. 12, pp. 1629–1633, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  123. K. V. Floros, H. Thomadaki, D. Florou, M. Talieri, and A. Scorilas, “Alterations in mRNA expression of apoptosis-related genes BCL2, BAX, FAS, caspase-3, and the novel member BCL2L12 after treatment of human leukemic cell line HL60 with the antineoplastic agent etoposide,” Annals of the New York Academy of Sciences, vol. 1090, pp. 89–97, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  124. K. V. Floros, H. Thomadaki, N. Katsaros, M. Taileri, and A. Scorilas, “mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin,” Biological Chemistry, vol. 385, no. 11, pp. 1099–1103, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  125. K. V. Floros, H. Thomadaki, G. Lallas, N. Katsaros, M. Talieri, and A. Scorilas, “Cisplatin-induced apoptosis in HL-60 human promyelocytic leukemia cells: differential expression of BCL2 and novel apoptosis-related gene BCL2L12,” Annals of the New York Academy of Sciences, vol. 1010, pp. 153–158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Thomadaki, A. Karaliota, C. Litos, and A. Scorilas, “Enhanced antileukemic activity of the novel complex 2,5-dihydroxybenzoate molybdenum(VI) against 2,5-dihydroxybenzoate, polyoxometalate of Mo(VI), and tetraphenylphosphonium in the human HL-60 and K562 leukemic cell lines,” Journal of Medicinal Chemistry, vol. 50, no. 6, pp. 1316–1321, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. H. Thomadaki, A. Karaliota, C. Litos, and A. Scorilas, “Enhanced concentration-dependent cytotoxic effect of the dinuclear copper(II) complex of L-carnitine [Cu2(L-carnitine) 2Cl2(H2O)2]Cl2, compared to L-carnitine or copper chloride dihydrate, in human leukemic cell lines,” Journal of Medicinal Chemistry, vol. 51, no. 13, pp. 3713–3719, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. H. Thomadaki, K. V. Floros, and A. Scorilas, “Molecular response of HL-60 cells to mitotic inhibitors vincristine and taxol visualized with apoptosis-related gene expressions, including the new member BCL2L12,” Annals of the New York Academy of Sciences, vol. 1171, pp. 276–283, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. C. Tse, A. R. Shoemaker, J. Adickes et al., “ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor,” Cancer Research, vol. 68, no. 9, pp. 3421–3428, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. M. H. Kang, H. K. Kang, B. Szymanska et al., “Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo,” Blood, vol. 110, no. 6, pp. 2057–2066, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. M. H. Kang, Z. Wan, Y. H. Kang, R. Sposto, and C. P. Reynolds, “Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation,” Journal of the National Cancer Institute, vol. 100, no. 8, pp. 580–595, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. V. Del Gaizo Moore, K. D. Schlis, S. E. Sallan, S. A. Armstrong, and A. Letai, “BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia,” Blood, vol. 111, no. 4, pp. 2300–2309, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. T. Oltersdorf, S. W. Elmore, A. R. Shoemaker et al., “An inhibitor of Bcl-2 family proteins induces regression of solid tumours,” Nature, vol. 435, no. 7042, pp. 677–681, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. M. Vogler, M. Butterworth, A. Majid et al., “Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia,” Blood, vol. 113, no. 18, pp. 4403–4413, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. M. Vogler, D. Dinsdale, X. M. Sun et al., “A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells,” Cell Death and Differentiation, vol. 15, no. 5, pp. 820–830, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. M. Vogler, S. D. Furdas, M. Jung, T. Kuwana, M. J. S. Dyer, and G. M. Cohen, “Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood,” Clinical Cancer Research, vol. 16, no. 16, pp. 4217–4225, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  137. V. Del Gaizo Moore, J. R. Brown, M. Certo, T. M. Love, C. D. Novina, and A. Letai, “Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737,” Journal of Clinical Investigation, vol. 117, no. 1, pp. 112–121, 2007. View at Google Scholar
  138. K. D. Mason, S. L. Khaw, K. C. Rayeroux et al., “The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia,” Leukemia, vol. 23, no. 11, pp. 2034–2041, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus